TY - JOUR
T1 - Do calcium antagonists contribute to gastro-oesophageal reflux disease and concomitant noncardiac chest pain?
AU - Hughes, Jeffery
AU - Lockhart, Judith
AU - Joyce, Andrew
PY - 2007
Y1 - 2007
N2 - What is already known about this subject: Calcium antagonists (CA) are listed in textbooks as potential causes of gastro-oesophageal reflux disease (GORD).There have been two studies which have documented increased use of acid suppressant therapy amongst patients taking CAs.
What this study adds: This study provides the first data on the frequency of exacerbation and precipitation of gastro-oesophageal reflux symptoms amongst users of CAs. It also provides evidence of the likely potential of the different CAs to cause such symptoms and highlights the need for a prospective study into CA therapy. The data from the study should heighten prescribers awareness of the potential of these agents to exacerbate/precipitate GORD, and to consider avoiding CAs in patients with GORD or withdrawing them in patients in whom GORD symptoms develop or worsen. Aims A cohort retrospective observational study was undertaken to determine the relationship between calcium antagonist (CA) use and gastro-oesophageal reflux disease (GORD), as well the ability of CAs to precipitate or exacerbate noncardiac chest pain, an atypical symptom of GORD. MethodsEligible patients were those prescribed CAs for hypertension without a history of ischaemic heart disease or nitrate use. Patients were recruited through 15 pharmacies (hospital 1, community 14). Patients giving informed consent were administered a standard questionnaire to obtain information including history of reflux symptoms before and during treatment with CAs, and the management of these symptoms. ResultsThree hundred and seventy-one participants were enrolled. Their mean age was 64 years (SD - 12.7 years), 51.2 were females and 48.8 males. Of the 130 patients with pre-existing gastrointestinal (GI) ......
AB - What is already known about this subject: Calcium antagonists (CA) are listed in textbooks as potential causes of gastro-oesophageal reflux disease (GORD).There have been two studies which have documented increased use of acid suppressant therapy amongst patients taking CAs.
What this study adds: This study provides the first data on the frequency of exacerbation and precipitation of gastro-oesophageal reflux symptoms amongst users of CAs. It also provides evidence of the likely potential of the different CAs to cause such symptoms and highlights the need for a prospective study into CA therapy. The data from the study should heighten prescribers awareness of the potential of these agents to exacerbate/precipitate GORD, and to consider avoiding CAs in patients with GORD or withdrawing them in patients in whom GORD symptoms develop or worsen. Aims A cohort retrospective observational study was undertaken to determine the relationship between calcium antagonist (CA) use and gastro-oesophageal reflux disease (GORD), as well the ability of CAs to precipitate or exacerbate noncardiac chest pain, an atypical symptom of GORD. MethodsEligible patients were those prescribed CAs for hypertension without a history of ischaemic heart disease or nitrate use. Patients were recruited through 15 pharmacies (hospital 1, community 14). Patients giving informed consent were administered a standard questionnaire to obtain information including history of reflux symptoms before and during treatment with CAs, and the management of these symptoms. ResultsThree hundred and seventy-one participants were enrolled. Their mean age was 64 years (SD - 12.7 years), 51.2 were females and 48.8 males. Of the 130 patients with pre-existing gastrointestinal (GI) ......
UR - http://www.blackwell-synergy.com/doi/full/10.1111/j.1365-2125.2007.02851.x
U2 - 10.1111/j.1365-2125.2007.02851.x
DO - 10.1111/j.1365-2125.2007.02851.x
M3 - Article
VL - 64
SP - 83
EP - 89
JO - British Journal of Clinical Pharmacology
JF - British Journal of Clinical Pharmacology
SN - 0306-5251
IS - 1
ER -